CellSure, L3C – FDA 483, Dec 8, 2023
An FDA inspection of Cellsure, L3C in Salt Lake City, UT, a stem cell own-label distributor, revealed significant deficiencies in their handling of human placenta and umbilical cord tissue. The firm failed to properly label HCT/Ps positive for communicable diseases, lacked adequate donor screening procedures, and had not established essential quality control, warehousing, distribution, or stability testing programs. Several of these critical issues were repeat observations, indicating persistent non-compliance.
ID · 407a6b6a-0e0a-4c9b-a366-207c155e5fc4
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.